Skip to main content
Erschienen in: Annals of Surgical Oncology 10/2009

01.10.2009 | Hepatobiliary Tumors

Clinical and Prognostic Significance of Urinary Trypsin Inhibitor in Patients with Hepatocellular Carcinoma After Hepatectomy

verfasst von: Isao Kikuchi, MD, Hiroshi Uchinami, MD, PhD, Hiroshi Nanjo, MD, PhD, Manabu Hashimoto, MD, PhD, Akio Nakajima, MD, PhD, Makoto Kume, MD, PhD, Ali Mencin, MD, Yuzo Yamamoto, MD, PhD

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Urinary trypsin inhibitor (UTI), produced in the liver, has been considered to suppress inflammation. The production of UTI may decrease after a hepatectomy and thereby increase the incidence of postoperative inflammation. This study investigated whether the changes in the UTI level affected the postoperative course in patients undergoing a hepatectomy for hepatocellular carcinoma (HCC). The prognostic significance of UTI was also analyzed.

Methods

The perioperative plasma UTI was measured in 25 HCC patients who underwent hepatic resection, and the correlation between the kinetics of UTI and clinicopathological factors was investigated. The expression of UTI in the resected specimens was examined by immunohistochemistry in 65 patients. Expression of UTI in the cancer cells were then correlated to both the liver pathology and the clinical outcomes in the corresponding patients.

Results

The plasma UTI level greatly decreased on the first postoperative day. This decrease significantly correlated with the resected tumor volume (r s = −.530, P = .006), but it had no influence on inflammatory complications. Immunohistochemistry revealed UTI expression in both noncancerous and cancerous lesions. An overexpression of UTI in HCC tissue was found to be an independent prognostic factor for early recurrence (P = .006).

Conclusions

Although UTI plasma levels were noted to decrease after the removal of an HCC tumor, this decrease did not lead to an increase in inflammatory complications. However, overexpression of UTI in cancer was found to be a risk factor for tumor recurrence after resection, suggesting that UTI expression may be a useful prognostic marker.
Literatur
1.
Zurück zum Zitat Benzoni E, Cojutti A, Lorenzin D, et al. Liver resective surgery: a multivariate analysis of postoperative outcome and complication. Langenbecks Arch Surg. 2007;392:45–54.CrossRefPubMed Benzoni E, Cojutti A, Lorenzin D, et al. Liver resective surgery: a multivariate analysis of postoperative outcome and complication. Langenbecks Arch Surg. 2007;392:45–54.CrossRefPubMed
2.
Zurück zum Zitat Zhou L, Rui JA, Wang SB, et al. Outcomes and prognostic factors of cirrhotic patients with hepatocellular carcinoma after radical major hepatectomy. World J Surg. 2007;31:1782–7.CrossRefPubMed Zhou L, Rui JA, Wang SB, et al. Outcomes and prognostic factors of cirrhotic patients with hepatocellular carcinoma after radical major hepatectomy. World J Surg. 2007;31:1782–7.CrossRefPubMed
3.
Zurück zum Zitat Shimada M, Takenaka K, Fujiwara Y, et al. Risk factors linked to postoperative morbidity in patients with hepatocellular carcinoma. Br J Surg. 1998;85:195–8.CrossRefPubMed Shimada M, Takenaka K, Fujiwara Y, et al. Risk factors linked to postoperative morbidity in patients with hepatocellular carcinoma. Br J Surg. 1998;85:195–8.CrossRefPubMed
4.
Zurück zum Zitat Shulman NR. A proteolytic inhibitor with anticoagulant activity separated from human urine and plasma. J Biol Chem. 1955;213:655–71.PubMed Shulman NR. A proteolytic inhibitor with anticoagulant activity separated from human urine and plasma. J Biol Chem. 1955;213:655–71.PubMed
5.
Zurück zum Zitat Hirose J, Ozawa T, Miura T, et al. Human neutrophil elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biol Pharm Bull. 1998;21:651–6.PubMed Hirose J, Ozawa T, Miura T, et al. Human neutrophil elastase degrades inter-alpha-trypsin inhibitor to liberate urinary trypsin inhibitor related proteins. Biol Pharm Bull. 1998;21:651–6.PubMed
6.
Zurück zum Zitat Sato N, Endo S, Kimura Y, et al. Influence of a human protease inhibitor on surgical stress induced immunosuppression. Dig Surg. 2002;19:300–5.CrossRefPubMed Sato N, Endo S, Kimura Y, et al. Influence of a human protease inhibitor on surgical stress induced immunosuppression. Dig Surg. 2002;19:300–5.CrossRefPubMed
7.
Zurück zum Zitat Uemura K, Murakami Y, Hayashidani Y, et al. Randomized clinical trial to assess the efficacy of ulinastatin for postoperative pancreatitis following pancreaticoduodenectomy. J Surg Oncol. 2008;98:309–13.CrossRefPubMed Uemura K, Murakami Y, Hayashidani Y, et al. Randomized clinical trial to assess the efficacy of ulinastatin for postoperative pancreatitis following pancreaticoduodenectomy. J Surg Oncol. 2008;98:309–13.CrossRefPubMed
8.
Zurück zum Zitat Ambiru S, Miyazaki M, Sasada K, et al. Effects of perioperative protease inhibitor on inflammatory cytokines and acute-phase proteins in patients with hepatic resection. Dig Surg. 2000;17:337–43.CrossRefPubMed Ambiru S, Miyazaki M, Sasada K, et al. Effects of perioperative protease inhibitor on inflammatory cytokines and acute-phase proteins in patients with hepatic resection. Dig Surg. 2000;17:337–43.CrossRefPubMed
9.
Zurück zum Zitat Kobayashi H, Suzuki M, Kanayama N, et al. Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade. Eur J Biochem. 2002;269:3945–57.CrossRefPubMed Kobayashi H, Suzuki M, Kanayama N, et al. Suppression of urokinase receptor expression by bikunin is associated with inhibition of upstream targets of extracellular signal-regulated kinase-dependent cascade. Eur J Biochem. 2002;269:3945–57.CrossRefPubMed
10.
Zurück zum Zitat Kobayashi H, Suzuki M, Tanaka Y, Kanayama N, Terao T. A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade. J Biol Chem. 2003;278:7790–9.CrossRefPubMed Kobayashi H, Suzuki M, Tanaka Y, Kanayama N, Terao T. A Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade. J Biol Chem. 2003;278:7790–9.CrossRefPubMed
11.
Zurück zum Zitat Yamamoto Y, Ikai I, Kume M, et al. New simple technique for hepatic parenchymal resection using a Cavitron Ultrasonic Surgical Aspirator and bipolar cautery equipped with a channel for water dripping. World J Surg. 1999;23:1032–7.CrossRefPubMed Yamamoto Y, Ikai I, Kume M, et al. New simple technique for hepatic parenchymal resection using a Cavitron Ultrasonic Surgical Aspirator and bipolar cautery equipped with a channel for water dripping. World J Surg. 1999;23:1032–7.CrossRefPubMed
12.
Zurück zum Zitat Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 2nd English ed. Tokyo: Kanehara, 2003. Liver Cancer Study Group of Japan. General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 2nd English ed. Tokyo: Kanehara, 2003.
13.
Zurück zum Zitat Lin SD, Endo R, Sato A, et al. Plasma and urine levels of urinary trypsin inhibitor in patients with acute and fulminant hepatitis. J Gastroenterol Hepatol. 2002;17:140–7.CrossRefPubMed Lin SD, Endo R, Sato A, et al. Plasma and urine levels of urinary trypsin inhibitor in patients with acute and fulminant hepatitis. J Gastroenterol Hepatol. 2002;17:140–7.CrossRefPubMed
14.
Zurück zum Zitat Jonsson-Berling BM, Ohlsson K, Rosengren M. Radioimmunological quantitation of the urinary trypsin inhibitor in normal blood and urine. Biol Chem Hoppe Seyler. 1989;370:1157–61.PubMed Jonsson-Berling BM, Ohlsson K, Rosengren M. Radioimmunological quantitation of the urinary trypsin inhibitor in normal blood and urine. Biol Chem Hoppe Seyler. 1989;370:1157–61.PubMed
15.
Zurück zum Zitat Uchinami H, Seki E, Brenner DA, D’Armiento J. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology. 2006;44:420–9.CrossRefPubMed Uchinami H, Seki E, Brenner DA, D’Armiento J. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology. 2006;44:420–9.CrossRefPubMed
16.
Zurück zum Zitat Tanaka Y, Kobayashi H, Suzuki M, et al. Reduced bikunin gene expression as a factor of poor prognosis in ovarian carcinoma. Cancer. 2003;98:424–30.CrossRefPubMed Tanaka Y, Kobayashi H, Suzuki M, et al. Reduced bikunin gene expression as a factor of poor prognosis in ovarian carcinoma. Cancer. 2003;98:424–30.CrossRefPubMed
17.
Zurück zum Zitat Noie T, Sugawara Y, Harihara Y, et al. Kinetics of urinary trypsin inhibitor in patients undergoing partial hepatectomy. Scand J Gastroenterol. 2001;36:410–6.CrossRefPubMed Noie T, Sugawara Y, Harihara Y, et al. Kinetics of urinary trypsin inhibitor in patients undergoing partial hepatectomy. Scand J Gastroenterol. 2001;36:410–6.CrossRefPubMed
19.
Zurück zum Zitat Taura K, Ikai I, Hatano E, et al. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg. 2006;244:265–73.CrossRefPubMed Taura K, Ikai I, Hatano E, et al. Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old. Ann Surg. 2006;244:265–73.CrossRefPubMed
20.
Zurück zum Zitat Yoshida E, Sumi H, Maruyama M, et al. Distribution of acid stable trypsin inhibitor immunoreactivity in normal and malignant human tissues. Cancer. 1989;64:860–9.CrossRefPubMed Yoshida E, Sumi H, Maruyama M, et al. Distribution of acid stable trypsin inhibitor immunoreactivity in normal and malignant human tissues. Cancer. 1989;64:860–9.CrossRefPubMed
21.
Zurück zum Zitat Tanaka Y, Kobayashi H, Suzuki M, et al. Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer. Gynecol Oncol. 2004;94:725–34.CrossRefPubMed Tanaka Y, Kobayashi H, Suzuki M, et al. Upregulation of bikunin in tumor-infiltrating macrophages as a factor of favorable prognosis in ovarian cancer. Gynecol Oncol. 2004;94:725–34.CrossRefPubMed
22.
Zurück zum Zitat Bourguignon J, Borghi H, Sesboue R, et al. Immunohistochemical distribution of inter-alpha-trypsin inhibitor chains in normal and malignant human lung tissue. J Histochem Cytochem. 1999;47:1625–32.PubMed Bourguignon J, Borghi H, Sesboue R, et al. Immunohistochemical distribution of inter-alpha-trypsin inhibitor chains in normal and malignant human lung tissue. J Histochem Cytochem. 1999;47:1625–32.PubMed
23.
Zurück zum Zitat Ogasawara S, Yano H, Momosaki S, et al. Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues. Oncol Rep. 2005;13:1043–8.PubMed Ogasawara S, Yano H, Momosaki S, et al. Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues. Oncol Rep. 2005;13:1043–8.PubMed
24.
Zurück zum Zitat Yoshioka I, Tsuchiya Y, Aozuka Y, et al. Urinary trypsin inhibitor suppresses surgical stress–facilitated lung metastasis of murine colon 26-L5 carcinoma cells. Anticancer Res. 2005;25:815–20.PubMed Yoshioka I, Tsuchiya Y, Aozuka Y, et al. Urinary trypsin inhibitor suppresses surgical stress–facilitated lung metastasis of murine colon 26-L5 carcinoma cells. Anticancer Res. 2005;25:815–20.PubMed
25.
Zurück zum Zitat Tsui KH, Chang PL, Feng TH, et al. Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells. Anticancer Res. 2008;28:1977–83.PubMed Tsui KH, Chang PL, Feng TH, et al. Down-regulation of matriptase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells. Anticancer Res. 2008;28:1977–83.PubMed
26.
Zurück zum Zitat Grondahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993;53:2513–21.PubMed Grondahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993;53:2513–21.PubMed
27.
Zurück zum Zitat Pappot H, Pedersen AN, Brunner N, Christensen IJ. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis. Lung Cancer. 2006;51:193–200.CrossRefPubMed Pappot H, Pedersen AN, Brunner N, Christensen IJ. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis. Lung Cancer. 2006;51:193–200.CrossRefPubMed
28.
Zurück zum Zitat Tonouchi A, Ohtsuka M, Ito H, et al. Relationship between pancreatic secretory trypsin inhibitor and early recurrence of intrahepatic cholangiocarcinoma following surgical resection. Am J Gastroenterol. 2006;101:1601–10.CrossRefPubMed Tonouchi A, Ohtsuka M, Ito H, et al. Relationship between pancreatic secretory trypsin inhibitor and early recurrence of intrahepatic cholangiocarcinoma following surgical resection. Am J Gastroenterol. 2006;101:1601–10.CrossRefPubMed
29.
Zurück zum Zitat Lee YC, Pan HW, Peng SY, et al. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer. 2007;43:736–44.CrossRefPubMed Lee YC, Pan HW, Peng SY, et al. Overexpression of tumour-associated trypsin inhibitor (TATI) enhances tumour growth and is associated with portal vein invasion, early recurrence and a stage-independent prognostic factor of hepatocellular carcinoma. Eur J Cancer. 2007;43:736–44.CrossRefPubMed
30.
Zurück zum Zitat Paju A, Vartiainen J, Haglund C, et al. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res. 2004;10:4761–8.CrossRefPubMed Paju A, Vartiainen J, Haglund C, et al. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res. 2004;10:4761–8.CrossRefPubMed
31.
Zurück zum Zitat Wiksten JP, Lundin J, Nordling S, et al. High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. Histopathology. 2005;46:380–8.CrossRefPubMed Wiksten JP, Lundin J, Nordling S, et al. High tissue expression of tumour-associated trypsin inhibitor (TATI) associates with a more favourable prognosis in gastric cancer. Histopathology. 2005;46:380–8.CrossRefPubMed
32.
Zurück zum Zitat McKeehan WL, Sakagami Y, Hoshi H, McKeehan KA. Two apparent human endothelial cell growth factors from human hepatoma cells are tumor-associated proteinase inhibitors. J Biol Chem. 1986;261:5378–83.PubMed McKeehan WL, Sakagami Y, Hoshi H, McKeehan KA. Two apparent human endothelial cell growth factors from human hepatoma cells are tumor-associated proteinase inhibitors. J Biol Chem. 1986;261:5378–83.PubMed
33.
Zurück zum Zitat Perry JK, Scott GK, Tse CA. Modulation of proliferation of cultured human cells by urinary trypsin inhibitor. Biochim Biophys Acta. 1994;1221:145–52.CrossRefPubMed Perry JK, Scott GK, Tse CA. Modulation of proliferation of cultured human cells by urinary trypsin inhibitor. Biochim Biophys Acta. 1994;1221:145–52.CrossRefPubMed
34.
Zurück zum Zitat Umeadi C, Kandeel F, Al-Abdullah IH. Ulinastatin is a novel protease inhibitor and neutral protease activator. Transplant Proc. 2008;40:387–9.CrossRefPubMed Umeadi C, Kandeel F, Al-Abdullah IH. Ulinastatin is a novel protease inhibitor and neutral protease activator. Transplant Proc. 2008;40:387–9.CrossRefPubMed
Metadaten
Titel
Clinical and Prognostic Significance of Urinary Trypsin Inhibitor in Patients with Hepatocellular Carcinoma After Hepatectomy
verfasst von
Isao Kikuchi, MD
Hiroshi Uchinami, MD, PhD
Hiroshi Nanjo, MD, PhD
Manabu Hashimoto, MD, PhD
Akio Nakajima, MD, PhD
Makoto Kume, MD, PhD
Ali Mencin, MD
Yuzo Yamamoto, MD, PhD
Publikationsdatum
01.10.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0622-2

Weitere Artikel der Ausgabe 10/2009

Annals of Surgical Oncology 10/2009 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.